Complications of Diabetes Therapy

Overview

Journal Endocrinol Metab Clin North Am

Publisher Elsevier

Specialty Endocrinology

Date 2013 Nov 30

PMID 24286957

Citations 9

Authors

Sarah D Corathers

Shawn Peavie

Marzieh Salehi

Affiliations

Soon will be listed here.

Abstract

Current strategies for the treatment of type 2 diabetes mellitus promote individualized plans to achieve target glucose levels on a patient-by-patient basis while minimizing treatment related risks. Maintaining glycemic control over time is a significant challenge because of the progressive nature of diabetes as a result of declining β-cell function. This article identifies complications of non-insulin treatments for diabetes. The major classes of medications are reviewed with special focus on target population, mechanism of action, effect on weight, cardiovascular outcomes and additional class-specific side effects including effects on bone. Effects on β-cell function are also highlighted.

Citing Articles

Decne., an endemic and rare subshrub from Arabian desert: antidiabetic and antihyperlipidemic effects of leaf hydroethanolic extracts.

Guetat A, Selmi S, Abdelwahab A, Abdelfattah M, Elhaj A, Mogharbel R Front Pharmacol. 2025; 16:1537071.

PMID: 39995414 PMC: 11847675. DOI: 10.3389/fphar.2025.1537071.

Exploring the Biological Effects of Anti-Diabetic Vanadium Compounds in the Liver, Heart and Brain.

Dayanand Y, Pather R, Xulu N, Booysen I, Sibiya N, Khathi A Diabetes Metab Syndr Obes. 2024; 17:3267-3278.

PMID: 39247428 PMC: 11380877. DOI: 10.2147/DMSO.S417700.

Analyzing Gene Expression After Administration of Low-Intensity Therapeutic Ultrasound in Human Islet Cells.

Hill J, Messina J, Jeremic A, Zderic V J Ultrasound Med. 2024; 43(6):1131-1141.

PMID: 38414281 PMC: 11093698. DOI: 10.1002/jum.16441.

New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment.

Haddad D, Dsouza V, Al-Mulla F, Madhoun A Int J Mol Sci. 2024; 25(1).

PMID: 38203742 PMC: 10779250. DOI: 10.3390/ijms25010571.

Protective potential of fish oil supplementation against insulin resistance and pancreatic islet damage in STZ-induced Wistar rats.

Titisari N, Fauzi A, Abdul Razak I, Samsulrizal N, Ahmad H Open Vet J. 2023; 13(8):983-990.

PMID: 37701670 PMC: 10495088. DOI: 10.5455/OVJ.2023.v13.i8.4.

References

Dunning B . New non-sulfonylurea insulin secretagogues. Expert Opin Investig Drugs. 1997; 6(8):1041-8. DOI: 10.1517/13543784.6.8.1041. View

Knowler W, Fowler S, Hamman R, Christophi C, Hoffman H, Brenneman A . 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374(9702):1677-86. PMC: 3135022. DOI: 10.1016/S0140-6736(09)61457-4. View

Phung O, Scholle J, Talwar M, Coleman C . Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010; 303(14):1410-8. DOI: 10.1001/jama.2010.405. View

Butler P, Elashoff M, Elashoff R, Gale E . A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?. Diabetes Care. 2013; 36(7):2118-25. PMC: 3687282. DOI: 10.2337/dc12-2713. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Molavi B, Rassouli N, Bagwe S, Rasouli N . A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag. 2008; 3(6):967-73. PMC: 2350137. View

Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo R . Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2006; 292(3):E871-83. DOI: 10.1152/ajpendo.00551.2006. View

Kadowaki T, Hagura R, KAJINUMA H, Kuzuya N, Yoshida S . Chlorpropamide-induced hyponatremia: incidence and risk factors. Diabetes Care. 1983; 6(5):468-71. DOI: 10.2337/diacare.6.5.468. View

Stenlof K, Cefalu W, Kim K, Alba M, Usiskin K, Tong C . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4):372-82. PMC: 3593184. DOI: 10.1111/dom.12054. View

10.

Vella A, Bock G, Giesler P, Burton D, Serra D, Ligueros Saylan M . Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007; 56(5):1475-80. DOI: 10.2337/db07-0136. View

11.

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

12.

Benbow A, Stewart M, Yeoman G . Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ. 2001; 322(7280):236. View

13.

Loke Y, Singh S, Furberg C . Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2008; 180(1):32-9. PMC: 2612065. DOI: 10.1503/cmaj.080486. View

14.

Lamanna C, Monami M, Marchionni N, Mannucci E . Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011; 13(3):221-8. DOI: 10.1111/j.1463-1326.2010.01349.x. View

15.

Derosa G, Maffioli P . Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin Ther. 2012; 34(6):1221-36. DOI: 10.1016/j.clinthera.2012.04.012. View

16.

Karara A, Dunning B, McLeod J . The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol. 2001; 39(2):172-9. DOI: 10.1177/00912709922007606. View

17.

Singh S, Loke Y, Furberg C . Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007; 30(8):2148-53. DOI: 10.2337/dc07-0141. View

18.

Kendall D, Riddle M, Rosenstock J, Zhuang D, Kim D, Fineman M . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5):1083-91. DOI: 10.2337/diacare.28.5.1083. View

19.

Baetta R, Corsini A . Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011; 71(11):1441-67. DOI: 10.2165/11591400-000000000-00000. View

20.

Kirpichnikov D, McFarlane S, Sowers J . Metformin: an update. Ann Intern Med. 2002; 137(1):25-33. DOI: 10.7326/0003-4819-137-1-200207020-00009. View